TG Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in New York, has recently made significant strides in its pursuit of innovative cancer treatments. As a key player in the biotechnology sector, TG Therapeutics focuses on the development and commercialization of pharmaceutical products aimed at addressing cancer and other therapeutic needs. The company’s efforts are particularly concentrated on therapies targeting hematological malignancies, with a specific emphasis on relapsed and refractory non-Hodgkin’s lymphoma.
On June 3, 2026, TG Therapeutics announced promising results from its Phase 1 trial of a subcutaneous formulation of ublituximab. This formulation serves as an alternative delivery method for the already approved drug BRIUMVI. The trial’s findings revealed encouraging pharmacokinetic, pharmacodynamic, safety, and tolerability outcomes. Notably, the new high-concentration, low-volume injection demonstrated comparable drug exposure to the existing intravenous regimen, while also being well tolerated by participants. These results support the ongoing evaluation of a quarterly dosing schedule in a Phase 3 study.
The potential implications of these findings are significant. Should the Phase 3 study confirm the efficacy and safety of the subcutaneous formulation, it could pave the way for a broader market for BRIUMVI. The company anticipates the release of top-line Phase 3 data later this year or early next year, which could potentially lead to the approval of this innovative subcutaneous product.
In addition to these developments, TG Therapeutics has confirmed that its chairman and CEO will be speaking at the prestigious Goldman Sachs 47th Annual Healthcare Conference in Miami. This event provides a platform for the company to share insights and updates with investors and industry stakeholders. A live webcast of the presentation will be available on the company’s investor site, offering broader access to the information shared.
As TG Therapeutics continues to advance its pipeline, the company remains a noteworthy entity within the health care sector. With a market capitalization of $5.3 billion and a price-to-earnings ratio of 13.18, the company is well-positioned to capitalize on its innovative approaches to cancer treatment. Investors and industry observers will undoubtedly keep a close watch on the upcoming Phase 3 data and the potential expansion of BRIUMVI’s market presence. For more detailed information on TG Therapeutics’ activities and offerings, interested parties can visit their official website or follow their trading on the Nasdaq stock exchange.
